Genio 2.1 is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for Obstructive Sleep Apnea.
As with the recent approval of Genio 2.1 by the FDA for use in the DREAM U.S. IDE pivotal study, this CE mark pertains entirely to the external components of the Genio system.
It will be available to all patients who have received Genio implants.
Genio 2.1 is designed to improve patient comfort and compliance with a new smartphone application and upgraded external activation chip.
Genio 2.1 offers patients daily feedback on therapy usage and the autonomy to adjust stimulation amplitude within pre-defined boundaries.
Physicians can fine-tune stimulation amplitude to determine the optimal comfort level for patients without compromising therapy efficacy.
Additional embedded sensors will allow physicians to further tailor therapy stimulation parameters based on patient position and throughout the night.
Price Action: NYXH shares closed 1.69% higher at $9.00 on Monday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.